Drug Budget: Row over cholesterol treatment
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.The National Health Service Executive is accused today of issuing misleading guidance to health authorities and GPs on the use of cholesterol- lowering drugs.
Health economists at the University of York and at Warwickshire health authority say the national guidance calls for a level of treatment that is unachievable, fails to state the likely benefits and ignores the question of cost effectiveness. In the British Medical Journal, the authors say that in Warwickshire's case, the use of such drugs in line with the guidance would cost pounds 8m, one fifth of the total drugs budget. They say the NHS Executive's advice is "simply inadequate."
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments